Arbutus Biopharma Corp (ABUS) stock
Close on Nov 11, 2026Market cap $767.65MP/E 3.5Yield –
Arbutus Biopharma Corp grew revenue 1142.6% to $181.49M over the twelve months to Sep 30, 2026. Free cash flow was -$39.64M. At the latest close the market valued the company at $767.65M, 3.5 times its earnings.
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Sep 30, 2026
Valuation
- Market cap
- $767.65M
- P/E ratio
- 3.5
- Price to sales
- 4.23
- Price to book
- 8.95
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $181.49M
- Net income
- $219.91M
- EPS, diluted
- $1.12
- Free cash flow
- -$39.64M
- Book value per share
- $0.43
- Diluted shares
- 200M
Trading
- Next earnings
- Mar 22, 2027 (estimated, before the open)
- Previous close
- $3.82
- Open
- $3.82
- Day's range
- $3.65 – $3.90
- Volume
- 2,129,510
- Average volume (20 days)
- 2,416,940
- Index membership
- Russell 2000 (since Jun 2021), Russell 3000 (since Aug 2021)
- Beta (5 years)
- 0.55
- 52-week range
- $3.50 – $5.45
- RSI (14 days)
- 39.8
- Volatility (1 year)
- 46.1%
- Relative volume
- 0.52×
- WACC
- 7.6%
Index membership is inferred from the holdings of funds that track each index (IWM, IWV), as reported to the SEC for Jun 30, 2026. Join dates come from quarterly fund reports since 2019, so they are accurate to the quarter.
Market cap history
Month-end market cap since 2011, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 11, 2026. The S&P 500 is measured by the SPY fund.
| Period | ABUS | S&P 500 | Difference | ABUS per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -8.1% | -2.4% | −5.6 pts | ||
| 3 months | -16.9% | -1.2% | −15.8 pts | ||
| Year to date | -19.3% | +12.3% | −31.6 pts | ||
| 1 year | -17.6% | +12.4% | −30.1 pts | ||
| 3 years | +119.2% | +78.8% | +40.4 pts | +29.9% | +21.4% |
| 5 years | +11.8% | +75.2% | −63.4 pts | +2.3% | +11.9% |
| 10 years | +38.6% | +311.1% | −272.5 pts | +3.3% | +15.2% |
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Arbutus Biopharma filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Arbutus Announces FDA Clinical Hold is Lifted on IND Application for AB-101, an Oral PD-L1 InhibitorNews
- News
- Results
- News
- Results
About Arbutus Biopharma
Pharmaceutical Preparations
Arbutus Biopharma Corporation is a clinical-stage biopharmaceutical company focused on therapies for infectious diseases, specifically chronic hepatitis B. Its pipeline features imdusiran, a subcutaneously administered ribonucleic acid interference drug, and AB-101, an oral checkpoint inhibitor intended to restore immune function. The company also licenses its proprietary lipid nanoparticle delivery technology to external partners. Its medical candidates target patients diagnosed with chronic hepatitis B, while its delivery platforms serve biopharmaceutical collaborators.
Company profile, executives and historyArbutus Biopharma stock: common questions
What is Arbutus Biopharma's stock price?
ABUS closed at $3.88 on Nov 11, 2026, up 1.57% on the day. Over the past 52 weeks it traded between $3.50 and $5.45.
What is Arbutus Biopharma's market cap?
Arbutus Biopharma was worth $767.65M at the close on Nov 11, 2026: the share price times the diluted shares outstanding.
What is ABUS's P/E ratio?
ABUS trades at 3.5 times earnings, based on diluted earnings per share of $1.12 over the twelve months to Sep 30, 2026.
How much revenue does Arbutus Biopharma make?
Arbutus Biopharma reported revenue of $181.49M for the twelve months to Sep 30, 2026, up 1142.6% from a year earlier.
Does Arbutus Biopharma pay a dividend?
No. Arbutus Biopharma has not paid a cash dividend over the last twelve months.
When does Arbutus Biopharma report earnings next?
Arbutus Biopharma is expected to report Q4 FY2026 results on Mar 22, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.
How has ABUS stock performed over the past year?
Including dividends, ABUS returned -17.6% over the past year, against +12.4% for the S&P 500.
How many ABUS shares are sold short?
20M shares were sold short at the latest FINRA report, 15.69% of the float, or 9.1 days of average trading volume.
Who are Arbutus Biopharma's competitors?
Companies most similar to Arbutus Biopharma by business, industry and size include ASMB, ANAB, ENTA, RCUS, KPTI.
See a number that looks wrong?